P.J. NESTEL, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Probucol, a cholesterol-lowering drug that has been in use in the United States for some time, is considered only moderately effective (1, 2). Low density lipoprotein (LDL) cholesterol is reduced less consistently with probucol than with cholestyramine and the simultaneous lowering of high density lipoprotein (HDL) cholesterol may be disadvantageous. (3) We saw a marked potentiation by probucol of the cholesterol lowering effect of cholestyramine. Because patients with familial hypercholesterolemia are often resistant to treatment with cholestyramine alone and need an additional drug such as nicotinic acid, or even plasmapheresis, we report our findings in six men
NESTEL P. Cholestyramine and Probucol Synergism. Ann Intern Med. 1982;97:622. doi: 10.7326/0003-4819-97-4-622_1
Download citation file:
Published: Ann Intern Med. 1982;97(4):622.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use